Reported Earlier, HUTCHMED Gains China Approval For ATLED (Fanregratinib) As Confirmatory Phase IIIb Trial Enrollment Continues For FGFR2-Positive Cholangiocarcinoma

뉴스 본문을 불러오고 있어요.

Reported Earlier, HUTCHMED Gains China Approval For ATLED (Fanregratinib) As Confirmatory Phase IIIb Trial Enrollment Continues For FGFR2-Positive Cholangiocarcinoma | 웨이프 WAPE

Reported Earlier, HUTCHMED Gains China Approval For ATLED (Fanregratinib) As Confirmatory Phase IIIb Trial Enrollment Continues For FGFR2-Positive Cholangiocarcinoma

기사 요약

관련 종목

댓글 —